For the complete activity, visit: [ Ссылка ]
In this activity, Alan Fleischer, Jr, MD, and Lindsay Strowd, MD, discuss the evolution in targeted treatments for atopic dermatitis based on improved understanding of pathophysiologic mechanisms. Supported by patient vignettes, they provide strategies for assessing the patient disease burden and its importance in developing an individualized treatment plan. Suggestions for greater patient engagement and improved self-management are also provided. The role and use of evidence-based nonpharmacologic and pharmacologic therapies are reviewed, focusing on dupilumab, for moderate-severe atopic dermatitis.
